The Lynx Group
Cholangiocarcinoma News

The Oncology Pipeline Offers Hope for Patients with Cholangiocarcinoma

December 2020, Vol 1, No 3

Despite the onslaught of the COVID-19 pandemic, researchers are hard at work to develop innovative therapies that will make a difference in the lives of patients with cancer.

At the 2020 Cholangiocarcinoma Summit, Filip Janku, MD, Associate Professor of Medicine, Investigational Cancer Therapeutics, Center Medical Director, Clinical and Translational Research Center, and Associate Member, Graduate School of Biomedical Sciences, the University of Texas M.D. Anderson Cancer Center, Houston, TX, delivered the keynote address, discussing drugs in the pipeline that may also be used for the treatment of patients with cholangiocarcinoma (CCA).

Multiple oncogenic molecular alterations have been identified in patients with CCA, Dr Janku said, and many of these mutations can effectively be targeted with cancer therapies. “Cholangiocarcinoma is…from the genomic standpoint, an extremely interesting disease,” Dr Janku suggested.

FGFR Inhibitors

Patients with advanced CCA whose disease progresses during or after first-line chemotherapy have few treatment options for second-line therapy. A major advance in the management of patients with CCA and FGFR2 fusions or other rearrangements was the FDA approval of pemigatinib (Pemazyre) in April 2020.

“Probably all of us noticed the pemigatinib approval for FGFR fusion cholangiocarcinoma. It was actually the first molecularly targeted therapy approved in cholangiocarcinoma,” said Dr Janku.

Other FGFR inhibitors that are in the advanced stage of development for CCA include infigratinib and futibatinib. These 2 investigational agents have exhibited efficacy in the second-line treatment, demonstrating safety profiles consistent with other drugs in this class.

In one study, the frequency of drug-resistant clones was lower with futibatinib, an inhibitor of several drug-resistant FGFR2 mutations, including the FGFR2 V565I/L gatekeeper mutations, with greater potency than any of the reversible FGFR inhibitors that were tested.1

Phase 3 clinical trials with infigratinib as well as with futibatinib are ongoing.

IDH Inhibitors

IDH1 or IDH2 mutations have been identified in 25% of patients diagnosed with CCA.2

Ivosidenib (Tibsovo), an oral targeted IDH1 inhibitor, was added to the National Comprehensive Cancer Network (NCCN) Guidelines for Hepatobiliary Cancers in June 2020 based on the strength of the clinical data that led to its FDA approval in 2020. Ivosidenib is indicated for the treatment of patients with acute myeloid leukemia (AML) and a susceptible IDH1 mutation, but it has not yet been approved by the FDA for the treatment of CCA.

Several other promising IDH inhibitors are in development. Vorasidenib is a pan-IDH inhibitor that inhibits the 2 isoforms IDH1 and IDH2 and is being studied in clinical trials for the treatment of glioma with IDH1 or IDH2 mutations.

HMPL306, another pan-IDH inhibitor, is being tested in a phase 1 clinical trial for relapsed or refractory AML with IDH mutations.

Another IDH1 inhibitor, LY3410738, is being investigated in a phase 1 clinical trial in patients with solid tumors, including CCA.

IDH inhibitors have a little bit more of a difficult development pathway. They are drugs that are arguably more cytostatic than cytotoxic, but at the same time, they have a very favorable safety profile. They definitely have a future, if not as a single agent, definitely as an agent for combinations with other therapies for cholangiocarcinoma,” Dr Janku said regarding the IDH inhibitors in development.

HER2 Inhibitors

HER2 amplifications have been observed in 11% to 20% of patients with CCA.2 Several clinical trials are investigating HER2-amplified gastrointestinal cancers, including CCA.

HER2 seems to be a very promising target, especially HER2 amplifications,” Dr Janku noted. “There are multiple studies led by companies, investigator-initiated groups, which essentially look at HER2 beyond gastric cancer and beyond breast cancer. They show interesting data, and cholangiocarcinoma is not an exception.”

BRCA, MEK, BRAF Mutations

Other molecular alterations that have been seen in patients with CCA are BRCA, MEK, and BRAF mutations.

“We found that quite a lot of patients with cholangiocarcinoma and IDH1 mutations had some simultaneous major alterations which were in multiple anchor genes,” Dr Janku said. These were “often associated with major pathways, such as MEK kinase pathways, such as KRAS or BRAF, or…DDR pathways, such as RN1A, APM, and BRCA,” he added.

The MEK and BRAF “inhibitors are extremely interesting. There are some very promising data from the basket trial, which was focusing on rare cancers with BRAF and MEK mutations,” Dr Janku said.

In this basket study reported in 2020, the FGFR inhibitors futibatinib, erdafitinib (Balversa), and infigratinib were evaluated in patients with CCA and BRAF V600 mutations. The data were very encouraging, demonstrating an overall response rate of 51% and overall survival of 14 months in patients who had received previous treatment with at least 1 line of therapy. Many of the patients had a response on the first restaging.

Cold Tumors

A predominant focus in oncology in general has been the development of immunotherapy strategies that increase the immunoresponsiveness of cold tumors. To address CCA that displays an immune desert phenotype or an immune-excluded phenotype, both of which are characteristically nonresponsive to treatment with immune checkpoint inhibitors, efforts are now underway to render cold tumors more sensitive to immunotherapies, Dr Janku said.


  1. Sootome H, Fujita H, Ito K, et al. Futibatinib is a novel irreversible FGFR1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80:4986-4997.
  2. Pellino A, Loupakis F, Cadamuro M, et al. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol. 2018;3:40.

Related Items

Ivosidenib Approved for Advanced or Metastatic Cholangiocarcinoma
Web Exclusives
Ivosidenib has been approved by the FDA for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
Recent Developments in Genomic-Driven Therapies for Cholangiocarcinoma
June/July 2021, Vol 2, No 2
Personalized medicine has expanded the treatment options for patients with cholangiocarcinoma (CCA). At the 2021 Annual Meeting of the Cholangiocarcinoma Foundation (CCF), Ghassan K. Abou-Alfa, MD, MBA, Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, discussed recent developments in personalized therapies, highlighting genomic alterations that are informing the new therapies for patients with CCA.
FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma
June/July 2021, Vol 2, No 2
The FDA granted accelerated approval to the kinase inhibitor infigratinib (Truseltiq) for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) that harbors an FGFR2 fusion or other rearrangement.
Futibatinib in Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements: Primary Results of FOENIX-CCA2 Presented at AACR 2021
June/July 2021, Vol 2, No 2
The primary results of the phase 2 FOENIX-CCA2 clinical trial of futibatinib in patients with previously treated intrahepatic cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements were presented by Lipika Goyal, MD, MPhil, Assistant Professor of Medicine, Massachusetts General Hospital, Boston, at the 2021 Annual Meeting of the American Association for Cancer Research (AACR).
Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
By Loretta Fala
June/July 2021, Vol 2, No 2
Cholangiocarcinoma (CCA) represents a group of heterogeneous cancers that originate in the bile ducts that connect the liver and gallbladder to the small intestine. Although the exact prevalence of CCA is unknown, CCA is a rare cancer; approximately 8000 new cases of CCA are diagnosed annually in the United States.
Incorporating FGFR Inhibitors into the Treatment Paradigm for Cholangiocarcinoma: Current Concepts and Future Directions
By Mitesh J. Borad, MD; Milind M. Javle, MD; Michael Morse, MD, FACP, MHS; Lewis R. Roberts, MB, ChB, PhD
June/July 2021, Vol 2, No 2
On January 15, 2021, experts in the management of patients with cholangiocarcinoma (CCA) convened for a virtual accredited continuing education satellite symposium held during the 2021 annual meeting of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The goal was to educate healthcare providers on various aspects of CCA, including epidemiology, current standards of care, unmet clinical needs, the safety and efficacy of fibroblast growth factor receptor (FGFR) inhibitors as second-line therapy, and practical approaches to incorporating FGFR inhibitors into the treatment paradigm for the disease.
The Latest Research in Biliary Tract Cancers Presented at ASCO GI 2021
March 2021, Vol 2, No 1
At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA.
What’s Next in Immunotherapy in Biliary Tract Cancers?
March 2021, Vol 2, No 1
The rationale for immunotherapy in biliary tract cancers is strong, because these cancers are inflammatory in nature, according to Abby Siegel, MD, MS, Executive Director and PDT Lead, Hepatobiliary Oncology, Global Clinical Development at Merck. Inroads are being made into biomarkers predictive of response to immunotherapy in biliary cancers, Dr Siegel said at the 2020 Annual Cholangiocarcinoma Summit.
Periadjuvant Approaches to Biliary Tract Cancers Offer Hope for Improved Outcomes
March 2021, Vol 2, No 1
A periadjuvant, or perioperative, approach to the treatment of biliary tract cancers, including cholangiocarcinoma (CCA), has several potential advantages that may offer an opportunity to improve outcomes in these diseases, said James Harding, MD, Regional Director, Early Drug Development, Memorial Sloan Kettering Cancer Center, New York, NY, at the 2020 Annual Cholangiocarcinoma Summit.
The Updated Staging System for Cholangiocarcinoma: Implications for Hilar and Intrahepatic Disease
March 2021, Vol 2, No 1
Flavio Rocha, MD, Hepatopancreatobiliary Surgeon, Virginia Mason Medical Center, Director of Research, Digestive Disease Institute, and Associate Medical Director of the Floyd and Delores Jones Cancer Institute, Seattle, WA, provided an overview of the changes made in the 8th edition of the AJCC’s tumor, node, metastasis (TNM) staging system at the 2020 Annual Cholangiocarcinoma Summit. These changes have direct implications for the management of patients with hilar or intrahepatic CCA.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: